<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Granger, Christopher</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apixaban Superior to Warfarin for Prevention of SSE in Patients with AF: Results from ARISTOTLE</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with atrial fibrillation, apixaban is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality according to primary results from the Apixaban for Reduction In STrOke and other ThromboemboLic Events in atrial fibrillation [ARISTOTLE; NCT00412984] trial.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>